A- A A+

Polysubstance Use Among Patients Treated With Buprenorphine From a National Urine Drug Test Database. 

Saloner B, Whitley P, LaRue L, Dawson E, Huskey A. 

JAMA Netw Open. 2021;4(9):e2123019. doi:10.1001/jamanetworkopen.2021.23019

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2784053

Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence. 

Lintzeris N, Dunlop A, Masters D (2019) 

NSW Ministry of Health, Sydney Australia

https://www.health.nsw.gov.au/aod/Publications/full-depot-bupe-interim-gl.pdf

Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series. 

Soyka M, Groß G. Am J Drug Alcohol Abuse. 2021 Aug 18:1-6. doi: 10.1080/00952990.2021.1963757. Epub ahead of print. PMID: 34407703.

https://www.tandfonline.com/doi/full/10.1080/00952990.2021.1963757

Beneficial Effects of Opioid Rotation to Buprenorphine/Naloxone on Opioid Misuse, Craving, Mental Health, and Pain Control in Chronic Non-Cancer Pain Patients with Opioid Use Disorder. 

Schellekens AFA, Veldman SE, Suranto ESD, van Rijswijk SM, van der Wal SEI, Schene AH, van Beek MHCT. 

J Clin Med. 2021 Aug 21;10(16):3727. doi: 10.3390/jcm10163727. PMID: 34442024; PMCID: PMC8396821.

https://www.mdpi.com/2077-0383/10/16/3727

Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia. 

Barnett A, Savic M, Lintzeris N, Bathish R, Arunogiri S, Dunlop AJ, Haber P, Graham R, Hayes V, Lubman DI.

Drug Alcohol Depend. 2021 Aug 11;227:108959. doi: 10.1016/j.drugalcdep.2021.108959. Epub ahead of print. PMID: 34450472.

https://www.sciencedirect.com/science/article/pii/S0376871621004543

High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder. 

Herring AA, Vosooghi AA, Luftig J, et al. 

JAMA Netw Open. 2021;4(7):e2117128. doi:10.1001/jamanetworkopen.2021.17128

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2781956

Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review. 

Adams KK, Machnicz M, Sobieraj DM. 

Addict Sci Clin Pract. 2021 Jun 8;16(1):36. doi: 10.1186/s13722-021-00244-8. PMID: 34103087; PMCID: PMC8186092.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186092/

Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder. 

Chappuy M, Meroueh F, Trojak B, Bachellier J, Bendimerad P, Kosim M, Hjelmström P, Nubukpo P, Brousse G, Rolland B. 

Patient Prefer Adherence. 2021 Jun 14;15:1259-1267. doi: 10.2147/PPA.S311674. PMID: 34163143; PMCID: PMC8214559.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214559/

Advancing emergency department-initiated buprenorphine. 

Huntley K, Einstein E, Postma T, Thomas A, Ling S, Compton W. 

J Am Coll Emerg Physicians Open. 2021 Jun 16;2(3):e12451. doi: 10.1002/emp2.12451. PMID: 34179878; PMCID: PMC8208651.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208651/

Schottland. Methadone alternative rolled out after Scottish prisons trial

A drug used in a pilot scheme to help prisoners affected by heroin addiction is to be rolled out across Scotland.

Buvidal acts as a replacement treatment for methadone, with patients receiving an injection every 28 days instead of taking daily medication. (BBC, UK, 08.07.2021)

https://www.bbc.com/news/uk-scotland-57748725

Webinar. Long-acting buprenorphine in the treatment of opioid dependence: striking the balance between greater freedom and strong engagement 

Watch the summer educational session led by Dr Julia Lewis, and joined by Dr Steve Brinksman that discussed the significance of taking a holistic approach when providing treatment for opioid dependence involving OST – particularly when using long-acting buprenorphine (LAB) formulations – to support adherence, good quality of life and mental health, and overall treatment success. (IOTOD, 02.07.2021, Webinar, 39:03)

https://iotodeducation.com/holistic-treatment-opioid-dependence-webinar

Australien. New heroin treatment option yielding positive results among patients at Melbourne injecting rooms

(…) The injectable is a slow-release version of buprenorphine available for patients to take once a week, once a month, or in Summer's case, once every six weeks.

(…)

It found 45 per cent of people weren't using opioids illicitly in the last week of the trial, week 24, compared to 2 per cent of those on placebo.

Dr Clark began prescribing and administering it to patients at the injecting room who were suitable and open to treatment at no cost. (abc.net, Australien, 15.06.2021)

https://www.abc.net.au/news/2021-06-15/new-heroin-treatment-helping-patients-in-melbourne/100197558

Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial. 

Kosten T, Aharonovich E, Nangia N, Zavod A, Akerman SC, Lopez-Bresnahan M, Sullivan MA. 

Addict Behav. 2020 Dec;111:106538. doi: 10.1016/j.addbeh.2020.106538. Epub 2020 Jul 3. PMID: 32777606.

https://www.sciencedirect.com/science/article/pii/S0306460320306687

Emergency physician perspectives on initiating buprenorphine/naloxone in the emergency department: A qualitative study. 

Dong KA, Lavergne KJ, Salvalaggio G, Weber SM, Xue CJ, Kestler A, Kaczorowski J, Orkin AM, Pugh A, Hyshka E. 

J Am Coll Emerg Physicians Open. 2021 Apr 29;2(2):e12409. doi: 10.1002/emp2.12409. PMID: 33969340; PMCID: PMC8082712.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082712/

Buprenorphine: Far Beyond the "Ceiling".

Infantino R, Mattia C, Locarini P, Pastore AL, Maione S, Luongo L. 

Biomolecules. 2021 May 31;11(6):816. doi: 10.3390/biom11060816. PMID: 34072706.

https://www.mdpi.com/2218-273X/11/6/816

Extended-Release Buprenorphine and Its Evaluation With Patient-Reported Outcomes. 

Compton WM, Volkow ND. 

JAMA Netw Open. 2021 May 3;4(5):e219708. doi: 10.1001/jamanetworkopen.2021.9708. PMID: 33970262.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779757

Prevalence and Characteristics of Chronic Pain in Buprenorphine and Methadone-Maintained Patients. 

Delorme J, Pennel L, Brousse G, Daulouède JP, Delile JM, Lack P, Gérard A, Dematteis M, Kabore JL, Authier N, Chenaf C; TOXIDOL Study group. 

Front Psychiatry. 2021 Apr 26;12:641430. doi: 10.3389/fpsyt.2021.641430. PMID: 33981257; PMCID: PMC8107279.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107279/

Using Microdosing to Induct Patients Into a Long-Acting Injectable Buprenorphine Depot Medication in Low Threshold Community Settings: A Case Study. 

Tay Wee Teck J, Baldacchino A, Gibson L, Lafferty C. 

Front Pharmacol. 2021 Mar 23;12:631784. doi: 10.3389/fphar.2021.631784. PMID: 33833682; PMCID: PMC8021866.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021866/

The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder. 

De Aquino JP, Parida S, Sofuoglu M. 

Clin Drug Investig. 2021 Apr 5:1–12. doi: 10.1007/s40261-021-01032-7. Epub ahead of print. PMID: 33818748; PMCID: PMC8020374.

https://pubmed.ncbi.nlm.nih.gov/33818748/

Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial. 

Lintzeris N, Dunlop AJ, Haber PS, et al. 

JAMA Netw Open. 2021;4(5):e219041. doi:10.1001/jamanetworkopen.2021.9041

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779751

Australien. ‘Game changer’ treatment cuts heroin use

An opioid treatment being introduced around Australia has been dubbed a game changer after dozens of users at Melbourne’s safe injecting room stopped taking heroin.

The Richmond site was among the first in Australia to provide depot buprenorphine, a slow-release injection given weekly or monthly, outside clinical trials after it was approved for use in September 2019. (Sydney Morning Herald, Australien, 10.05.2021)

https://www.theage.com.au/national/victoria/game-changer-treatment-cuts-heroin-use-20210505-p57p2i.html

Poisoning Deaths Associated With Buprenorphine Almost Always Involve Sedatives or Other Opioids

Buprenorphine has a favorable safety profile because of its partial agonist and ceiling respiratory depression effects. However, there are poisoning deaths associated with it. Researchers used data from autopsies of sudden and unexpected deaths in Finland, which has high rates of illicit buprenorphine use, to investigate the extent to which these deaths were associated with the use of other substances. In Finland, all sudden and unexpected deaths (12% of all deaths in this study period) are investigated with autopsy, including comprehensive toxicology in 75%. (Alcohol, Other Drugs, and Health: Current Evidence, USA, März-April 2021)

http://www.bu.edu/aodhealth/2021/04/29/poisoning-deaths-associated-with-buprenorphine-almost-always-involve-sedatives-or-other-opioids/

Sixmo: Buprenorphin-6-Monatsimplantat erhält Zulassungsempfehlung 

Das Buprenorphin-haltige 6-Monatsimplantat Sixmo hat eine Zulassungsempfehlung für die Substitutionstherapie von stabilen Opiatabhängigen mit einem maximalen Buprenorphin-Bedarf von 8 mg/Tag erhalten. (Gelbe Liste, 16.05.2021)

https://www.gelbe-liste.de/nachrichten/sixmo-buprenorphin-implantat-zulassungsempfehlung

EMA. Sixmo (Buprenorphin) - Übersicht über Sixmo und warum es in der EU zugelassen ist

Was ist Sixmo und wofür wird es angewendet?

Sixmo ist ein Implantat, das zur Behandlung einer Abhängigkeit von Opioiden wie Heroin oder Morphin angewendet wird. Es enthält den Wirkstoff Buprenorphin.Sixmo wird bei Erwachsenen angewendet, die bereits stabil sind und Buprenorphin unter der Zunge (höchstens 8 mg/Tag) anwenden und außerdem medizinische, soziale und psychologische Behandlung erhalten. (EMA – European Medicine Agency 2019)

https://www.ema.europa.eu/en/documents/overview/sixmo-epar-overview_de.pdf

Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. 

Larance B, Degenhardt L, Grebely J, Nielsen S, Bruno R, Dietze P, Lancaster K, Larney S, Santo T Jr, Shanahan M, Memedovic S, Ali R, Farrell M. 

Addiction. 2020 Jul;115(7):1295-1305. doi: 10.1111/add.14941. Epub 2020 Feb 5. PMID: 31860767; PMCID: PMC7292758.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292758/

Increased Treatment Engagement and Adherence: Flexible Management with Prolonged-Release Buprenorphine in Treatment of Opioid Dependence. 

Hard B. 

Case Rep Psychiatry. 2021 Feb 27;2021:6657350. doi: 10.1155/2021/6657350. PMID: 33728083; PMCID: PMC7936910.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936910/

Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies. 

Fava M, Thase ME, Trivedi MH, Ehrich E, Martin WF, Memisoglu A, Nangia N, Stanford AD, Yu M, Pathak S. 

Mol Psychiatry. 2020 Jul;25(7):1580-1591. doi: 10.1038/s41380-018-0284-1. Epub 2018 Oct 29. PMID: 30374191; PMCID: PMC7303008.

https://www.nature.com/articles/s41380-018-0284-1

Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route. 

Kharidia, J., Howgate, E.M., Laffont, C.M., Liu, Y. and Young, M.A. (2021), 

Clinical Pharmacology in Drug Development. doi.org/10.1002/cpdd.934

https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.934

Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis. 

McCormack L, Ponce J, Chatterjee A, Tan JK. 

JAAD Case Rep. 2021 Jan 11;10:22-24. doi: 10.1016/j.jdcr.2020.12.031. PMID: 33732840; PMCID: PMC7941000.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941000/

Micro-dosing Intravenous Buprenorphine to Rapidly Transition From Full Opioid Agonists. 

Thakrar AP, Jablonski L, Ratner J, Rastegar DA. 

J Addict Med. 2021 Mar 19. doi: 10.1097/ADM.0000000000000838. Epub ahead of print. PMID: 33758112.

Abstract

https://pubmed.ncbi.nlm.nih.gov/33758112/